TICKERNERD
Menu
REGNREGNHealthcare · Biotechnology

REGN Stock Forecast: Regeneron Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$781
−1.48% on the day

The 28 Wall Street analysts covering Regeneron Pharmaceuticals, Inc. hold a median 12-month price target of $854 — +9.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 12 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$80.5B
Ticker Nerd rank
93 / 100
Median analyst target
$854
Analysts covering
28
Revenue$4.3B+16.7% y/y
Operating income$1.4B
Net income$1.3B
Free cash flow$521.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.3%
1M
−1.8%
YTD
+1.6%
1Y
+38.2%
From 52W high
−8.3%
From 52W low
+41.4%
$553
$852
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

REGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Regeneron Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
93 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
96
Value
95
Revisions
93
Quality
83
Issuance
78
Momentum
76
Growth
63
Accruals
39
Size
3

Volatility (96): The share price has been relatively steady.

Accruals (39): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (3): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

REGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on REGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$500$600$700$800$900$1,000$1,100Oct 25Jan 26Apr 26Jul 26REGNHigh $1,030Median $854Low $730

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says28 analysts
18 Buy9 Hold1 Sell
Low $730Median $854High $1,030

The green dot is the last close — the median target sits +9.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 10 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
10 Sept 2026HSBCMaintainsBuy$800 → $920
17 Aug 2026Leerink PartnersMaintainsMarket Perform$641 → $824
3 Aug 2026CitigroupMaintainsNeutral$700 → $740
3 Aug 2026CitigroupMaintainsNeutral—
3 Aug 2026GuggenheimMaintainsBuy$1,000 → $1,030
3 Aug 2026GuggenheimMaintainsBuy—
31 July 2026Cantor FitzgeraldMaintainsOverweight—
31 July 2026Cantor FitzgeraldMaintainsOverweight$750 → $795
31 July 2026Morgan StanleyMaintainsEqual-Weight$730 → $758
31 July 2026Morgan StanleyMaintainsEqual-Weight—
31 July 2026RBC CapitalMaintainsSector Perform$696 → $737
31 July 2026RBC CapitalMaintainsSector Perform—
31 July 2026Truist SecuritiesMaintainsBuy—
31 July 2026Truist SecuritiesMaintainsBuy$769 → $772
31 July 2026Wells FargoMaintainsEqual-Weight—
31 July 2026Wells FargoMaintainsEqual-Weight$700 → $750
21 July 2026GuggenheimMaintainsBuy$995 → $1,000
21 July 2026GuggenheimMaintainsBuy—
9 July 2026Piper SandlerMaintainsOverweight$855 → $854
9 July 2026Piper SandlerMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. REGN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

REGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Regeneron Pharmaceuticals, Inc. returned +38.2% against +17.5% for the S&P 500, dividends included.

REGN vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Oct 25Jan 26Apr 26Jul 26REGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

REGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+15.8%
Analysts raising
23
Analysts cutting
0
Fundamentals

Regeneron Pharmaceuticals, Inc. (REGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
19.3×

Cheaper than 38% of US stocks

Price / sales
5.2×

Cheaper than 24% of US stocks

Price / book
2.5×

Cheaper than 38% of US stocks

EV / EBITDA
15.5×

Cheaper than 22% of US stocks

Growth & margins
Revenue growth (YoY)
16.7%

Higher than 65% of US stocks

Earnings growth (YoY)
−6.8%

Higher than 29% of US stocks

Gross margin
86.6%

Higher than 95% of US stocks

Operating margin
33.1%

Higher than 88% of US stocks

Net margin
27.9%

Higher than 87% of US stocks

Returns & dividend
Return on equity
14.0%

Higher than 72% of US stocks

Return on assets
6.5%

Higher than 83% of US stocks

Dividend yield
0.5%

Higher than 9% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Regeneron Pharmaceuticals, Inc. (REGN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Regeneron Pharmaceuticals, Inc. has a market value of $80.5B and an enterprise value of $72.7B.

  • Revenue in the twelve months to 30 June 2026: $15.5B. The latest quarter grew 16.7% year on year.

  • Net income over the same four quarters: $4.3B, a 27.9% net margin.

  • Diluted earnings per share, trailing twelve months: $40.46.

  • Free cash flow in the twelve months to 30 June 2026: $3.6B, after $920.9M of capital spending.

  • Regeneron Pharmaceuticals, Inc. spent $3.9B on share buybacks and $378.5M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 103.1M.

  • Trailing P/E: 19.3×; forward P/E: 12.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.48%, paying out 9% of earnings.

  • Regeneron Pharmaceuticals, Inc. employs 15,410 people — $1.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

REGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
REGNRegeneron Pharmaceuticals, Inc.$80.5B
93
MRNAModerna, Inc.$57.5B
82
VRTXVertex Pharmaceuticals, Inc.$130.8B
74
RVMDRevolution Medicines, Inc.$42.5B
40
RPRXRoyalty Pharma plc$33.8B
87
ALNYAlnylam Pharmaceuticals, Inc.$32.9B
50
ROIVRoivant Sciences Ltd.$29.2B
38

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Regeneron Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest REGN news & analysis

Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth

MarketBeat · 12 Sept 2026positive

Regeneron executives discussed growth plans across its commercial portfolio, upcoming regulatory milestones, and pipeline programs during a Wells Fargo investor conference appearance, with EYLEA HD and DUPIXENT cited as key growth drivers into 2026.

Why it matters — A REGN watcher would care because the company's outlook for EYLEA HD, DUPIXENT, and future regulatory milestones indicates where near-term growth and pipeline progress may come from.

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN

PRNewsWire · 10 Sept 2026negative

A law firm, SueWallSt, has reminded Regeneron shareholders of a September 14, 2026 lead plaintiff deadline in a lawsuit against the company. The lawsuit alleges Regeneron minimized statistical and protocol risks in its Phase III Fianlimab-Libtayo trial disclosures, including the potential impact of FDA-related amendments on progression-free survival analysis.

Why it matters — A REGN watcher would care because the lawsuit puts the company's clinical-trial risk disclosures under scrutiny, which could affect investor confidence in its pipeline transparency.

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

GlobeNewsWire · 10 Sept 2026negative

SBS Law (Schall, Brown & Schwartz LLP) reminded investors of a securities fraud class action lawsuit against Regeneron Pharmaceuticals, alleging violations of the Securities Exchange Act of 1934 and Rule 10b-5. The firm is inviting Regeneron investors to lead the lawsuit.

Why it matters — Regeneron watchers would care because the company faces a securities fraud class action that could carry legal and financial implications for shareholders.

FAQ

Frequently asked questions about REGN stock

What is the REGN stock price forecast for 2026-2027?

The 28 Wall Street analysts covering Regeneron Pharmaceuticals, Inc. have a median 12-month price target of $854, with estimates ranging from $730 to $1,030. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is REGN stock a buy right now?

Of the 28 analysts covering Regeneron Pharmaceuticals, Inc., 18 rate it a Buy, 9 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Regeneron Pharmaceuticals, Inc. 93 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank REGN?

As at 12 Sept 2026, Regeneron Pharmaceuticals, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (96 of 100).

Will REGN stock go up?

No one can know that. What the data says: the median 12-month target from 28 analysts implies +9.3% from the last close, and Ticker Nerd's factor model ranks Regeneron Pharmaceuticals, Inc. 93 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the REGN stock forecast for 2030?

No analyst covering Regeneron Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for REGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $730 to $1,030 over the next 12 months.

How has REGN stock performed over the past year?

Regeneron Pharmaceuticals, Inc. returned +38.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Regeneron Pharmaceuticals, Inc. do?

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases.

What is the latest news on REGN?

The most recent item we track (MarketBeat, 12 Sept 2026): "Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth". Regeneron executives discussed growth plans across its commercial portfolio, upcoming regulatory milestones, and pipeline programs during a Wells Fargo investor conference appearance, with EYLEA HD and DUPIXENT cited as key growth drivers into 2026.

Company

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases. Its portfolio spans treatments in eye care, immunology, oncology, cardiovascular and metabolic disease, infectious disease, hematology, and rare disorders. The company is known for combining laboratory research, clinical development, and in-house manufacturing to advance biologic therapies and antibody-based medicines. Regeneron also works on product candidates across multiple therapeutic areas, supporting a broad drug pipeline alongside its marketed medicines. Regeneron Pharmaceuticals, Inc. plays an important role in the healthcare market through its focus on specialty therapies designed for complex and often chronic medical conditions.

CEO Dr. Leonard S. Schleifer M.D., Ph.D. · 15,410 employees · United States · https://www.regeneron.com